INTERVIEW: Bayer Sees Solid Asian Growth After Strong Year
This article was originally published in PharmAsia News
Driven mainly by new launches and underlying economic growth, Bayer is bullish over the prospects for its Asia-Pacific pharma business, predicting continued mid-term expansion ahead of the overall market.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.